EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM

Daniel R Richardson iD, Allison M Deal, Carl J Mhina, Matthew Washko, Amy C Cole iD, Norah L Crossnohere iD, Kah Poh Loh, Ethan Basch iD, Stephanie B Wheeler, William A Wood, John F P Bridges, Thomas W LeBlanc und 1 weitere

MDM Policy & Practice · 2026-01 · 11 (1)

DOI: 10.1177/23814683261440935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MDM Policy & Practice, online erschienen am 07.05.2026. Verfasst von Daniel R Richardson und 12 weiteren Autor:innen. Beteiligte Einrichtung: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The recent expansion of treatment options for older adults with blood cancers has increased the necessity for understanding patient preferences and values to inform treatment decision making. Currently, no values elicitation measures have been validated for clinical use in this population. Values-HM (Values elicitation measure for Hematologic Malignancies) is a novel values elicitation measure based on best–worst scaling. It was developed specifically for older adults with blood cancers involving multiple stakeholders including patients, caregivers, and clinicians.

Objective

The objective of this study was to test the preliminary validity, reliability, and acceptability of this measure for clinical use based on US Food and Drug Administration and International Society for Pharmacoeconomics and Outcomes Research guidance.

Results

Twenty-nine adults aged ≥60 y with newly diagnosed lymphoma, leukemia, myelodysplastic syndrome, and multiple myeloma were enrolled. Most patients were White (97%). Most patients (88%) felt that the measure was relevant to them, showed their real preferences (73%), and was acceptable to clarify their preferences (68%). The measure demonstrated discriminant validity of importance scores and convergent validity for most patients (77%) with a ranking exercise of the treatment values. Cognitive interviews with 10 participants suggested question comprehension, outcome understanding, and appropriate judgment. Data from 18 participants who completed the measure more than once provide some evidence for the reliability of the measure to capture repeated values over time.

Conclusions

These initial data suggest that Values-HM may be acceptable to patients and valid and reliable to capture patient values. Additional data are needed to confirm these findings in a larger and more diverse sample. This trial was registered at www.clinicaltrials.gov as #NCT05061095. Highlights Values-HM is a novel values elicitation measure designed based on best–worst scaling for adults with blood cancers. Values-HM appears to be acceptable to patients and may be valid and reliable to capture patient values in clinical care.

Schlagwörter

Stichwörter der Autor:innen

Decision Making, SharedHematologic NeoplasmsPatient PreferencePatient-Reported Outcome Measuresbest-worst scalingolder adultstreatment decision makingvalues elicitation

Autor:innen und Institutionen

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Duke University Department of Population Health Sciences, Durham, NC, USA.
  • The Ohio State University, Columbus, OH, USA.
  • Division of Hematology/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
  • Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

ORCID-Profile: Daniel R Richardson, Amy C Cole, Norah L Crossnohere, Ethan Basch

Zitieren

APA

Richardson, D. R., Deal, A. M., Mhina, C. J., Washko, M., Cole, A. C., Crossnohere, N. L., Loh, K. P., Basch, E., Wheeler, S. B., Wood, W. A., Bridges, J. F. P., LeBlanc, T. W., & Bennett, A. V. (2026). Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM. MDM Policy & Practice, 11(1). https://doi.org/10.1177/23814683261440935

Vancouver

Richardson DR, Deal AM, Mhina CJ, Washko M, Cole AC, Crossnohere NL, et al. Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM. MDM Policy & Practice. 2026;11(1). doi:10.1177/23814683261440935

BibTeX
@article{Richardson2026,
  author = {Richardson, Daniel R and Deal, Allison M and Mhina, Carl J and Washko, Matthew and Cole, Amy C and Crossnohere, Norah L and Loh, Kah Poh and Basch, Ethan and Wheeler, Stephanie B and Wood, William A and Bridges, John F P and LeBlanc, Thomas W and Bennett, Antonia V},
  title = {Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM},
  journal = {MDM Policy & Practice},
  year = {2026},
  volume = {11},
  number = {1},
  doi = {10.1177/23814683261440935}
}
Kostenlos starten →